Filing Flows › TherapeuticsMD (TXMD) › Q4 2024
TherapeuticsMD (TXMD) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 27, 2025
TherapeuticsMD (TXMD) reported revenue of $667K for the fourth quarter 2024 (Q4 2024), +33% from a year earlier and +22% from the quarter before. Operating margin was -97.8%, net earnings $252K (37.8% of revenue).
TherapeuticsMD, Q4 2024: revenue $667K (+33% year over year), operating margin -97.8%, net earnings $252K, operating cash flow $17K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $667K | +22% | +33% |
| Operating profit | −$652K | — | — |
| Net earnings | $252K | — | — |
| Operating cash flow | $17K | — | — |
What changed
Revenue was $667K in Q4 2024, up 33% year over year and up 22% from the previous quarter.
Operating costs exceeded revenue by $652K, an operating margin of -97.8%. Net earnings were $252K. The tax line was a benefit of $169K on pre-tax earnings of $83K. Non-operating items added $735K, 886% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $17K, 7% of net earnings. Non-cash charges added back $100K of depreciation and amortization and $24K of share-based compensation. Working capital and other items used $359K.
Questions
What was TherapeuticsMD's revenue in the fourth quarter 2024?
TherapeuticsMD (TXMD) reported revenue of $667K for the fourth quarter 2024 (Q4 2024), +33% from a year earlier and +22% from the quarter before.
Was TherapeuticsMD profitable in the fourth quarter 2024?
Operating loss was $652K (-97.8% of revenue) and net earnings $252K.
Source: TherapeuticsMD 10-K on SEC EDGAR.